Abstract

BackgroundIsocitrate dehydrogenase (IDH) mutation and 1p19q codeletion status have been identified as significant markers for therapy and prognosis in lower-grade glioma (LGG). The current study aimed to construct a combined machine learning-based model for predicting the molecular subtypes of LGG, including (1) IDH wild-type astrocytoma (IDHwt), (2) IDH mutant and 1p19q non-codeleted astrocytoma (IDHmut-noncodel), and (3) IDH-mutant and 1p19q codeleted oligodendroglioma (IDHmut-codel), based on multiparametric magnetic resonance imaging (MRI) radiomics, qualitative features, and clinical factors.MethodsA total of 335 patients with LGG (WHO grade II/III) were retrospectively enrolled. The sum of 5,929 radiomics features were extracted from multiparametric MRI. Selected robust, non-redundant, and relevant features were used to construct a random forest model based on a training cohort (n = 269) and evaluated on a testing cohort (n = 66). Meanwhile, preoperative MRIs of all patients were scored in accordance with Visually Accessible Rembrandt Images (VASARI) annotations and T2-fluid attenuated inversion recovery (T2-FLAIR) mismatch sign. By combining radiomics features, qualitative features (VASARI annotations and T2-FLAIR mismatch signs), and clinical factors, a combined prediction model for the molecular subtypes of LGG was built.ResultsThe 17-feature radiomics model achieved area under the curve (AUC) values of 0.6557, 0.6830, and 0.7579 for IDHwt, IDHmut-noncodel, and IDHmut-codel, respectively, in the testing cohort. Incorporating qualitative features and clinical factors into the radiomics model resulted in improved AUCs of 0.8623, 0.8056, and 0.8036 for IDHwt, IDHmut-noncodel, and IDHmut-codel, with balanced accuracies of 0.8924, 0.8066, and 0.8095, respectively.ConclusionThe combined machine learning algorithm can provide a method to non-invasively predict the molecular subtypes of LGG preoperatively with excellent predictive performance.

Highlights

  • Diffuse lower-grade glioma [LGG, World Health Organization (WHO) grades II and III] is a primary brain tumor that originates from glial or precursor cells and presents as a heterogeneous disease [1]

  • Isocitrate dehydrogenase (IDH) mutation and 1p19q codeletion status have been identified as significant markers for therapy and prognosis in lower-grade glioma (LGG)

  • Incorporating qualitative features and clinical factors into the radiomics model resulted in improved area under the curve (AUC) of 0.8623, 0.8056, and 0.8036 for IDH wild-type (IDHwt), IDHmut-noncodel, and IDHmut-codel, with balanced accuracies of 0.8924, 0.8066, and 0.8095, respectively

Read more

Summary

Introduction

Diffuse lower-grade glioma [LGG, World Health Organization (WHO) grades II and III] is a primary brain tumor that originates from glial or precursor cells and presents as a heterogeneous disease [1]. The 2016 WHO classification divides LGG into three molecular subtypes based on isocitrate dehydrogenase (IDH) mutation and 1p19q codeletion status [1]: IDH wild-type (IDHwt) [2], IDH mutants with euploid 1p19q (IDHmut-noncodel), and [3] IDH mutants carrying 1p19q codeletion (IDHmut-codel) [2, 3]. Isocitrate dehydrogenase (IDH) mutation and 1p19q codeletion status have been identified as significant markers for therapy and prognosis in lower-grade glioma (LGG). The current study aimed to construct a combined machine learning-based model for predicting the molecular subtypes of LGG, including [1] IDH wild-type astrocytoma (IDHwt), [2] IDH mutant and 1p19q non-codeleted astrocytoma (IDHmutnoncodel), and [3] IDH-mutant and 1p19q codeleted oligodendroglioma (IDHmut-codel), based on multiparametric magnetic resonance imaging (MRI) radiomics, qualitative features, and clinical factors

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call